JP6964576B2 - 置換４−アザインドール及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用 - Google Patents

置換４−アザインドール及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用 Download PDF

Info

Publication number
JP6964576B2
JP6964576B2 JP2018500737A JP2018500737A JP6964576B2 JP 6964576 B2 JP6964576 B2 JP 6964576B2 JP 2018500737 A JP2018500737 A JP 2018500737A JP 2018500737 A JP2018500737 A JP 2018500737A JP 6964576 B2 JP6964576 B2 JP 6964576B2
Authority
JP
Japan
Prior art keywords
pyridin
pyrrolo
methyl
phenyl
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018500737A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018520170A5 (cg-RX-API-DMAC7.html
JP2018520170A (ja
Inventor
シー． クロビアン，クリスタ
エー． レタヴィク，マイケル
シー． レッシュ，ジェイソン
ソイオデ−ジョンソン，アキノラ
エル． ウォール，ジェシカ
Original Assignee
ヤンセン ファーマシューティカ エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ．ベー． filed Critical ヤンセン ファーマシューティカ エヌ．ベー．
Publication of JP2018520170A publication Critical patent/JP2018520170A/ja
Publication of JP2018520170A5 publication Critical patent/JP2018520170A5/ja
Priority to JP2021138906A priority Critical patent/JP7369743B2/ja
Application granted granted Critical
Publication of JP6964576B2 publication Critical patent/JP6964576B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
JP2018500737A 2015-07-09 2016-07-07 置換４−アザインドール及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用 Active JP6964576B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021138906A JP7369743B2 (ja) 2015-07-09 2021-08-27 置換４－アザインドール及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562190416P 2015-07-09 2015-07-09
US62/190,416 2015-07-09
PCT/US2016/041339 WO2017007938A1 (en) 2015-07-09 2016-07-07 Substituted 4-azaindoles and their use as glun2b receptor modulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021138906A Division JP7369743B2 (ja) 2015-07-09 2021-08-27 置換４－アザインドール及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用

Publications (3)

Publication Number Publication Date
JP2018520170A JP2018520170A (ja) 2018-07-26
JP2018520170A5 JP2018520170A5 (cg-RX-API-DMAC7.html) 2019-07-25
JP6964576B2 true JP6964576B2 (ja) 2021-11-10

Family

ID=56497884

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018500737A Active JP6964576B2 (ja) 2015-07-09 2016-07-07 置換４−アザインドール及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用
JP2021138906A Active JP7369743B2 (ja) 2015-07-09 2021-08-27 置換４－アザインドール及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021138906A Active JP7369743B2 (ja) 2015-07-09 2021-08-27 置換４－アザインドール及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用

Country Status (25)

Country Link
US (2) US9963447B2 (cg-RX-API-DMAC7.html)
EP (1) EP3319963B1 (cg-RX-API-DMAC7.html)
JP (2) JP6964576B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180026760A (cg-RX-API-DMAC7.html)
CN (1) CN108026094B (cg-RX-API-DMAC7.html)
AU (1) AU2016291158B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018000468A2 (cg-RX-API-DMAC7.html)
CA (1) CA2991765C (cg-RX-API-DMAC7.html)
CY (1) CY1123007T1 (cg-RX-API-DMAC7.html)
DK (1) DK3319963T3 (cg-RX-API-DMAC7.html)
EA (1) EA033197B1 (cg-RX-API-DMAC7.html)
ES (1) ES2781867T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20200410T1 (cg-RX-API-DMAC7.html)
HU (1) HUE047460T2 (cg-RX-API-DMAC7.html)
IL (1) IL256758A (cg-RX-API-DMAC7.html)
LT (1) LT3319963T (cg-RX-API-DMAC7.html)
MA (1) MA42397B1 (cg-RX-API-DMAC7.html)
MD (1) MD3319963T2 (cg-RX-API-DMAC7.html)
MX (1) MX2018000352A (cg-RX-API-DMAC7.html)
PL (1) PL3319963T3 (cg-RX-API-DMAC7.html)
PT (1) PT3319963T (cg-RX-API-DMAC7.html)
SI (1) SI3319963T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202000134T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017007938A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201800827B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021193099A (ja) * 2015-07-09 2021-12-23 ヤンセン ファーマシューティカ エヌ．ベー． 置換４−アザインドール及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3180329T (pt) 2014-08-15 2020-06-08 Janssen Pharmaceuticals Inc Triazóis como inibidores do recetor nr2b
USRE49517E1 (en) 2014-08-15 2023-05-02 Janssen Pharmaceuticals, Inc. Pyrazoles
CN109071488B (zh) 2016-02-10 2021-08-13 詹森药业有限公司 取代的1,2,3-三唑作为nr2b-选择性nmda调节剂
TW201819376A (zh) * 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
US11447503B2 (en) 2019-06-14 2022-09-20 Janssen Pharmaceutica Nv Pyridine carbamates and their use as GLUN2B receptor modulators
JP7346441B2 (ja) * 2018-04-04 2023-09-19 ヤンセン ファーマシューティカ エヌ．ベー． 置換ピリジン及びピリミジン並びにｇｌｕｎ２ｂ受容体調節物質としてのそれらの使用
TW202112774A (zh) * 2019-06-14 2021-04-01 比利時商健生藥品公司 經取代之吡唑并－吡啶醯胺及其作為ｇｌｕｎ２ｂ受體調節劑之用途
JP2022536424A (ja) * 2019-06-14 2022-08-16 ヤンセン ファーマシューティカ エヌ．ベー． 置換ヘテロ芳香族ピラゾロピリジン及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用
CA3142998A1 (en) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Pyrazine carbamates and their use as glun2b receptor modulators
KR20220020917A (ko) * 2019-06-14 2022-02-21 얀센 파마슈티카 엔.브이. 치환된 피라졸로[4,3-b]피리딘 및 GLUN2B 수용체 조절제로서의 이들의 용도
MX2021015500A (es) 2019-06-14 2022-02-10 Janssen Pharmaceutica Nv Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b.
PH12021552839A1 (en) 2019-06-14 2022-10-03 Janssen Pharmaceutica Nv Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators
CN114621125B (zh) * 2020-12-14 2024-07-09 中国科学技术大学 Nlrp3炎症小体抑制剂及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1490364B1 (en) * 2002-03-28 2007-09-26 Eisai R&D Management Co., Ltd. 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders
TW200604183A (en) 2004-02-18 2006-02-01 Astrazeneca Ab Triazole compounds and their use as metabotropic glutamate receptor antagonists
US20060183758A1 (en) * 2005-02-17 2006-08-17 Cb Research And Development, Inc. Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans
US7807704B2 (en) * 2006-03-30 2010-10-05 Chemocentryx, Inc. Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2
PE20090717A1 (es) * 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
KR20100017372A (ko) 2007-05-25 2010-02-16 애보트 게엠베하 운트 콤파니 카게 향대사성 글루타메이트 수용체 2（ｍｇｌｕ2 수용체）의 포지티브 조절자로서의 헤테로사이클릭 화합물
WO2009005821A1 (en) 2007-07-03 2009-01-08 Edward Scott Carlson Support apparatus for climbing plants
EP2194045A4 (en) 2007-08-30 2011-09-21 Takeda Pharmaceutical Substituted pyrazole derivative
EP2215073A4 (en) 2007-10-31 2011-04-06 Merck Sharp & Dohme SLEEP MODULATION WITH NR2B RECEPTOR ANTAGONISTS
RU2499598C2 (ru) 2008-03-27 2013-11-27 Евотек Интернациональ Гмбх Способы лечения нарушений с применением селективного антагониста nr2b-подтипа nmda рецепторов
WO2010016490A1 (ja) 2008-08-05 2010-02-11 第一三共株式会社 イミダゾピリジン－２－オン誘導体
AU2009304293B2 (en) * 2008-10-16 2012-04-26 Addex Pharma S.A. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
EP3037421A3 (en) 2008-11-25 2016-11-30 University Of Rochester Mlk inhibitors and methods of use
TWI625121B (zh) * 2009-07-13 2018-06-01 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
WO2011156245A2 (en) 2010-06-09 2011-12-15 Merck Sharp & Dohme Corp. Positive allosteric modulators of mglur2
WO2013130855A1 (en) 2012-03-02 2013-09-06 Takeda Pharmaceutical Company Limited Indazole derivatives
WO2014124651A1 (en) * 2013-02-15 2014-08-21 Københavns Universitet Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists
EP2970200A1 (en) * 2013-03-13 2016-01-20 Abbvie Inc. Pyridine cdk9 kinase inhibitors
RU2680100C9 (ru) * 2013-03-15 2019-04-18 Плексксикон Инк. Гетероциклические соединения и их применения
CN103626767A (zh) * 2013-12-04 2014-03-12 上海药明康德新药开发有限公司 区域选择性的氮杂吲哚及其合成方法
PT3180329T (pt) 2014-08-15 2020-06-08 Janssen Pharmaceuticals Inc Triazóis como inibidores do recetor nr2b
USRE49517E1 (en) 2014-08-15 2023-05-02 Janssen Pharmaceuticals, Inc. Pyrazoles
HRP20200410T1 (hr) 2015-07-09 2020-08-21 Janssen Pharmaceutica Nv Supstituirani 4-azaindoli i njihova upotreba kao modulatora glun2b receptora
CN109071488B (zh) 2016-02-10 2021-08-13 詹森药业有限公司 取代的1,2,3-三唑作为nr2b-选择性nmda调节剂
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021193099A (ja) * 2015-07-09 2021-12-23 ヤンセン ファーマシューティカ エヌ．ベー． 置換４−アザインドール及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用
JP7369743B2 (ja) 2015-07-09 2023-10-26 ヤンセン ファーマシューティカ エヌ．ベー． 置換４－アザインドール及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用

Also Published As

Publication number Publication date
CA2991765C (en) 2023-10-03
JP2021193099A (ja) 2021-12-23
BR112018000468A2 (pt) 2018-09-18
ES2781867T3 (es) 2020-09-08
DK3319963T3 (da) 2020-02-03
MD3319963T2 (ro) 2020-05-31
SI3319963T1 (sl) 2020-02-28
SMT202000134T1 (it) 2020-05-08
PT3319963T (pt) 2020-04-09
HUE047460T2 (hu) 2020-04-28
EA201890245A1 (ru) 2018-06-29
ZA201800827B (en) 2019-09-25
MA42397B1 (fr) 2020-02-28
KR20180026760A (ko) 2018-03-13
US9963447B2 (en) 2018-05-08
CA2991765A1 (en) 2017-01-12
US20180208595A1 (en) 2018-07-26
HK1255160A1 (en) 2019-08-09
LT3319963T (lt) 2020-03-25
IL256758A (en) 2018-03-29
CN108026094B (zh) 2021-02-09
AU2016291158A1 (en) 2018-02-01
EP3319963B1 (en) 2020-01-08
CN108026094A (zh) 2018-05-11
AU2016291158B2 (en) 2020-04-30
CY1123007T1 (el) 2021-10-29
PL3319963T3 (pl) 2020-06-01
US20170008890A1 (en) 2017-01-12
US10377753B2 (en) 2019-08-13
HRP20200410T1 (hr) 2020-08-21
EA033197B1 (ru) 2019-09-30
WO2017007938A1 (en) 2017-01-12
JP7369743B2 (ja) 2023-10-26
JP2018520170A (ja) 2018-07-26
MX2018000352A (es) 2018-08-15
EP3319963A1 (en) 2018-05-16

Similar Documents

Publication Publication Date Title
JP6964576B2 (ja) 置換４−アザインドール及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用
JP7001682B2 (ja) 置換１Ｈ－イミダゾ［４，５－ｂ］ピリジン－２（３Ｈ）－オン及びＧＬＵＮ２Ｂ受容体調節因子としてのそれらの使用
JP7600433B2 (ja) カルボキシ－ベンズイミダゾールｇｌｐ－１ｒ調節化合物
JP7097373B2 (ja) キナーゼ阻害剤としてのアミノトリアゾロピリジン
JP6387360B2 (ja) 変異ｉｄｈの阻害薬としての３−ピリミジン−４−イル−オキサゾリジン−２−オン
JP5931752B2 (ja) 縮環複素環誘導体
RU2632870C2 (ru) Трициклические гетероциклические соединения и ингибиторы jak
WO2019101086A1 (zh) 卤代烯丙基胺类ssao/vap-1抑制剂及其应用
KR20150129000A (ko) Pde4 억제제로서 치환된 피리딘 및 피라진 화합물
TW202115054A (zh) 經取代的雜芳族吡唑并－吡啶及其作為ｇｌｕｎ２ｂ受體調節劑的用途
ES2976515T3 (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad del receptor APJ
WO2024178390A1 (en) Covalent modifiers of akt1 and uses thereof
JP2024543207A (ja) 新規ｈｄａｃ阻害剤及びその治療的使用
TW202332427A (zh) 新穎雜環化合物
KR20190097258A (ko) Pde2 억제제로서 치환된 피라졸로피리미디논 화합물
TW202542138A (zh) 與含ｐａｔａｔｉｎ樣磷脂酶結構域蛋白３ＩＭ結合的化合物及其用於治療肝病之用途
JP2022536522A (ja) 置換ピラゾロ－ピリジンアミド及びｇｌｕｎ２ｂ受容体調節因子としてのその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190620

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190620

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200623

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200923

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210827

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210827

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210903

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210907

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210928

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211019

R150 Certificate of patent or registration of utility model

Ref document number: 6964576

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250